Relay Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Relay Therapeutics, Inc. (RLAY) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $9.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Relay Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $9.18M, a 36.70% decline year-over-year.
- Relay Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.54M, a 45.47% decline year-over-year.
- Relay Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $15.53M, a 30.94% decline year-over-year.
- Relay Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $14.50M, a 45.96% decline year-over-year.
- Relay Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $62.42M, a 33.69% decline from fiscal 2024.
- Relay Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $94.14M, a 9.42% increase from fiscal 2023.
- Relay Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $86.03M, a 53.25% increase from fiscal 2022.
- Relay Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $56.14M, a 15.86% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.18M 10-Q · filed 2026-08-06 | $19.72M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $10.54M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $62.42M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $15.53M 10-Q · filed 2025-11-06 | $30.03M derived: sum of 2 quarters · filed 2026-08-06 | $49.35M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $14.50M 10-Q · filed 2026-08-06 | $33.83M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $19.32M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $94.14M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $22.48M 10-Q · filed 2025-11-06 | $49.32M derived: sum of 2 quarters · filed 2025-11-06 | $76.50M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $26.83M 10-Q · filed 2025-11-06 | $54.02M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $27.19M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $86.03M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $21.84M 10-Q · filed 2024-11-06 | $45.25M derived: sum of 2 quarters · filed 2024-11-06 | $66.76M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $23.41M 10-Q · filed 2024-11-06 | $44.93M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $21.52M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $56.14M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $13.72M 10-Q · filed 2023-11-02 | $28.87M derived: sum of 2 quarters · filed 2023-11-02 | $42.32M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $15.15M 10-Q · filed 2023-11-02 | $28.60M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $13.46M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $48.45M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $12.42M 10-Q · filed 2022-11-03 | $28.57M derived: sum of 2 quarters · filed 2022-11-03 | $38.24M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $16.15M 10-Q · filed 2022-11-03 | $25.82M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $9.67M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $31.96M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $11.93M 10-Q · filed 2021-11-10 | $15.96M derived: sum of 2 quarters · filed 2021-11-10 | $17.42M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $4.03M 10-Q · filed 2021-11-10 | $5.49M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $1.46M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $4.46M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $1.25M 10-Q · filed 2020-11-12 | $2.33M derived: sum of 2 quarters · filed 2020-11-12 | $3.15M derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $1.08M 10-Q · filed 2020-11-12 | $1.90M derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | $820.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |